Strides Pharma Science Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024
For the full year, sales was INR 40,511.24 million compared to INR 36,883.87 million a year ago. Revenue was INR 40,908.25 million compared to INR 37,787.15 million a year ago. Net loss was INR 706.14 million compared to INR 2,026.35 million a year ago. Basic loss per share from continuing operations was INR 13.72 compared to INR 24.56 a year ago. Diluted loss per share from continuing operations was INR 13.72 compared to INR 24.56 a year ago. Basic loss per share was INR 7.76 compared to INR 22.49 a year ago. Diluted loss per share was INR 7.76 compared to INR 22.49 a year ago.